31 articles - From Friday Mar 17 2023 to Friday Mar 24 2023
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
| J Crohns Colitis |
Anal high-risk human papillomavirus infection, squamous intraepithelial lesions and anal cancer in patients with inflammatory bowel disease: a systematic review and meta-analysis. The incidence of anal cancer is higher in UC than in CD, with the exception of perianal CD. There is limited and heterogenous data on anal high-risk human papillomavirus infection and squamous intraepithelial lesions prevalence in this population. |
RCT, clinical trials, retrospective studies, etc…
| Inflamm Bowel Dis |
Assessing the Impact of COVID-19 on IBD Outcomes Among Vulnerable Patient Populations in a Large Metropolitan Center. For IBD populations, during COVID-19, in both hospital settings, emergency department visits, hospitalizations, outpatient surgery, and clinic visits were reduced compared with the year prior. Patients with lower socioeconomic status and limited English proficiency reported facing more challenges with changes to healthcare delivery, healthcare access, and conveying changes in IBD activity. These results highlight the need for payors and providers to specifically attend to those populations most susceptible to these systemic and lasting changes in care delivery and promote greater equity in healthcare. |
Composite Assessment Using Intestinal Ultrasound and Calprotectin Is Accurate in Predicting Histological Activity in Ulcerative Colitis: A Cohort Study. Intestinal ultrasound is an accurate noninvasive marker of histological disease activity in UC, the accuracy of which is further enhanced when used in composite with FC. This can reduce the need for colonoscopy in routine care by supporting accurate point-of-care decision-making in patients with UC. |
Epidemiology of Inflammatory Bowel Disease in a Cohort of US Black Women. In a large prospective cohort of US Black women, we found that the incidence of IBD was similar to previously published estimates in US White women. Future studies should focus on identifying risk factors for IBD in Black individuals in the United States. |
Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis. Matching-adjusted indirect comparison results suggest superiority of filgotinib 200 mg over vedolizumab IV in terms of clinical response and corticosteroid-free clinical remission in certain patient populations, noting small sample sizes and wide CIs, which may aid the selection of advanced therapies for moderately to severely active UC. A potential increased risk of serious adverse events was reported for filgotinib 200 mg vs vedolizumab IV and tofacitinib 5 mg, but findings should be interpreted with caution owing to underlying imbalances observed between the placebo groups of SELECTION and comparator trials. |
Speaker Diversity and Audience Ratings at a National Inflammatory Bowel Diseases Conference. Gender diversity at inflammatory bowel disease conferences is improving. However, there remain significant gaps, particularly in racial diversity and improving perceptions of early-career speakers. These data should inform program committees for future gastroenterology conferences. |
The Underappreciated Role of Secretory IgA in IBD. In both cases, de novo recruitment of IgA ASC to the intestinal lamina propria is compromised, leading to bacterial overgrowth, dysbiosis, and lethal colitis. Thus, despite the safe and effective use of anti-integrin antibodies in patients with IBD, much remains to be learned about their various cell targets. |
| J Crohns Colitis |
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients With Moderately to Severely Active Crohn's Disease. Tesnatilimab was well tolerated. The efficacy of tesnatilimab in patients with CD was significant for the primary endpoint in Part 1; however, no dose-response signal was detected for the primary endpoint in Part 2. Based on these inconsistent findings, tesnatilimab was not considered an effective treatment for patients with CD and no further development is planned. |
Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial. FIL200 induced and maintained benefits relative to placebo regardless of previous biologic use; however, the estimated therapeutic benefit was greatest in biologic-naïve patients and patients previously treated with one biologic or biologic MoA class. |
Serum immune profiling in pediatric Crohn's disease demonstrates stronger immune modulation with first-line infliximab than conventional therapy and pre-treatment profiles predict clinical response to both treatments. FL-IFX leads to stronger reductions and modulates more immune proteins than CONV. Stratification on pre-treatment profiles of IFX-modulated proteins directly relates to maintenance of remission without treatment escalation. |
Transient Suppression of Bacterial Populations Associated with Gut Health is Critical in Success of Exclusive Enteral Nutrition for Children with Crohn's Disease. These observations taken together suggest that successful outcomes of EEN are marked by a temporary emergence of microbial populations that are rare in healthy individuals, and a concomitant reduction in microbes that are commonly associated with gut homeostasis. Our work is a first attempt to highlight individual-specific, complex environmental factors that influence microbial response in EEN. This model offers a novel, alternative viewpoint to traditional taxonomic strategies used to characterize associations with health and disease states. |
| Liver Transpl |
Characterization of social determinants of health of a liver transplant referral population. Among the referral population, several potential barriers to evaluation and selection for LT were identified, including poverty, educational attainment, access to healthy food, and access to technology. This approach to characterization of a transplant center's referral population by geographic location and associated SDOH demonstrates a model for identifying disparities in a referral population and potential barriers to evaluation that can be used to inform targeted interventions for disparities in LT access. |
Lung cancer screening using low-dose CT and FDG-PET in liver transplant recipients. A carefully followed multidisciplinary lung cancer screening algorithm in LTR, that includes FDG-PET and LDCT, allows lung cancer to be diagnosed at an early stage, while reducing unnecessary invasive procedures. |
Serum and plasma protein biomarkers associated with frailty in patients with cirrhosis. These biomarkers represent inflammatory, musculoskeletal, and endocrine/metabolic systems, reflecting the multiple physiologic derangements observed in frailty. These data lay the foundation for confirmatory work and development of a laboratory frailty index for patients with cirrhosis to improve diagnosis and prognostication. |
Validation of MELD 3.0 scoring system in East Asian patients with cirrhosis awaiting liver transplantation. Predictive power of MELD-based system is lower in Asian populations than Western countries. Nonetheless, the MELD 3.0 score with albumin was significantly better in predicting short term prognosis of East Asian patients on the LT waitlist than the current allocation system, original MELD. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Am J Clin Nutr |
| Inflamm Bowel Dis |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Inflamm Bowel Dis |
| Liver Transpl |
Letters to the editors and authors’ replies